The use of low-molecular-weight heparin bridging therapy for secondary prevention after an acute stroke is being questioned after new evidence showed increased risks of ischaemic recurrence and intracerebral bleeding. It may be preferable to use direct acting oral anticoagulants (DOACs) that have a rapid onset and are reversible rather than slow-onset vitamin K antagonists such ...
Use DOACs to avoid bridging therapy risks in stroke patients: neurologist
By Michael Woodhead
26 Jun 2019